Canagliflozin increased urinary glucose excretion in a dose-dependent manner and produced statistically significant reductions in body weight compared with placebo ( least squares mean percent changes from baseline of -@ % , -@ % , -@ % , and -@ % with canagliflozin @ , @ , and @ mg and placebo ; P < @ for all comparisons ) .